Loading…
Loading…
Compass Pathways (NASDAQ: CMPS - Get Free Report) is expected to release its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to announce earnings of ($0.3857) per share for the quarter. Investors are encouraged to explore the company's upcoming Q2 2026 earning report for the latest details on the
Compass Pathways (NASDAQ:CMPS)'s COMP360 treatment model may face fewer regulatory hurdles as new Phase II analysis distinguishes the company's psychological support approach from psychotherapy, Jefferies analysts have highlighted. In a note reviewing a post-hoc analysis of Compass Pathways (NASDAQ:CMPS)' completed Phase II open-label trial of COMP360 in post-traumatic stress disorder (PTSD), Jefferies wrote that the study provided further detail on how the company's treatment model separates monitoring and support during dosing sessions from traditional talk therapy.
Compass Pathways (NASDAQ:CMPS)'s COMP360 treatment model may face fewer regulatory hurdles as new Phase II analysis distinguishes the company’s...
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a post-hoc analysis of support methods used in an open-label Phase 2 study of investigational COMP360 synthetic psilocybin treatment in patients with post-traumatic stress disorder (PTSD). Documented speech production between participants and support providers during treatment a.
Psychedelic drug developers including AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Compass Pathways (NASDAQ:CMPS) and Cybin Inc. (NYSE-A:CYBN, FRA:R7E) could...
CleanSpark Inc (NASDAQ:CLSK) shares surged more than 12% after the company announced a 20-year lease agreement for its Sandersville, Georgia data center...
Tower Semiconductor (NASDAQ:TSEM) shares rose 13% on Tuesday after the company announced a strategic expansion of its silicon photonics, silicon germanium...
Compass Pathways NASDAQ: CMPS said new 26-week data from its Phase 3 COMP006 trial further support the durability and safety profile of COMP360, its investigational psilocybin therapy for treatment-resistant depression, as the company works toward a potential U.S. launch in the first half of 2027.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for CMPS and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.